纳斯达克 · 生物技术 · USD
BlossomHill Therapeutics, Inc. (BLSM) 股票分析
BlossomHill Therapeutics, Inc.（BLSM）是在纳斯达克上市的生物技术股票，以美元交易。
最后更新: 2026年10月21日
价格走势
暂无价格数据
悬停查看每日收盘价。虚线表示区间起始价。
BLSM 关键统计数据
数据截至2026年10月21日交易
- 开盘价
- $14.94
- 前收盘价
- $14.40
- 当日波动区间
- 14.51–15.64
- 52周波动区间
- 14.70–27.99
- 成交量
- 7.62万
估值
- 市值
- $4.76亿
- 市盈率
- 亏损
- 每股收益（近12个月）过去十二个月归属于每股的利润。
- −4.65
财务（财年）
- 营业收入（财年）
- $0.00
- 净利润（财年）
- −$6055.50万
- 流通股数
- 3178.49万
股息与日期
- 财报日期
- 2026年11月16日预计
- 平均成交量
- 25.01万
仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。
关键数据
BlossomHill Therapeutics, Inc.（BLSM）的市值为$4.76亿。
2025财年，BLSM的营业收入为$0.00。
BLSM 各财年营收与利润
财年截至十二月| 财年 | 营业收入 | 净利润 | 净利率 |
|---|---|---|---|
| 2025 | $0.00 | −$6055.50万 | — |
| 2024 | $0.00 | −$3069.50万 | — |
| 财年 | 营业收入 | 毛利 | 营业利润 | 净利润 | 净利率 |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$6402.40万 | −$6055.50万 | — |
| 2024 | $0.00 | — | −$3640.10万 | −$3069.50万 | — |
为公司报告货币口径的年度公布数据。 数据截至2025年12月31日。
最新新闻
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
YahooBlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027
BenzingaLeerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
BenzingaGuggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
BenzingaBlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
YahooBlossomHill Therapeutics Q2 EPS $(8.75)
Benzinga
全部19篇文章 ↓收起 ↑
BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update
InvestorsHubBlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
YahooBlossomHill Therapeutics Announces Updated Data From Ongoing Phase 1/2 SOLARA Trial Of BH-30643 In NSCLC Patients With Secondary EGFR Resistance Mutations Such As EGFR C797S
BenzingaBlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
YahooLifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32
BenzingaLeerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36
BenzingaBlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
YahooJP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28
BenzingaGuggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30
BenzingaHC Wainwright & Co. Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $35
BenzingaBlossomhill Says FDA Grants Fast Track Designation To BH-30643 For Treatment Of Adult Patients With Advanced Or Metastatic EGFR C797S-Positive NSCLC After Prior Treatment With Third-Gen EGFR Tyrosine Kinase Inhibitor
BenzingaBlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
YahooBlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise
SeekingAlpha
新闻由第三方来源提供。不构成投资建议。
分析
数据生成以上所有数字均在每日重新生成时从本页自身的数据中读取。仅供参考，不构成投资建议。 数据截至2026年10月21日。
相关生物技术股票
VRTX
查看所有生物技术股票 →
Vertex Pharmaceuticals Incorporated
$1329.45亿
MRNAModerna, Inc.
$981.36亿
REGNRegeneron Pharmaceuticals, Inc.
$829.48亿
ARGXargenx SE
$559.72亿
ONCBeOne Medicines AG
$439.67亿
RVMDRevolution Medicines, Inc.
$416.41亿
医疗保健热门股票
LLY
查看所有医疗保健股票 →
Eli Lilly and Company
$1.13万亿
JNJJohnson & Johnson
$6212.24亿
ABBVAbbVie Inc.
$5032.75亿
UNHUnitedHealth Group Incorporated
$3742.97亿
MRKMerck & Co., Inc.
$3697.80亿